ALX Oncology welcomes Dr. Itziar Canamasas to its Board of Directors

– USA, CA –  ALX Oncology Holdings Inc., (Nasdaq: ALXO) a clinical-stage immuno-oncology company today announced the appointment of Dr. Itziar Canamasas (Ph.D.) to its Board of Directors effective April 11, 2022, bringing more than 20 years of biopharmaceutical industry experience and expertise in driving business growth and operational excellence.

“We are excited to welcome Dr. Canamasas to our Board during an important time in ALX Oncology’s continued evolution. Dr. Canamasas provides a proven track record of successful oncology product launches and transformational strategic expertise to ALX Oncology that will be instrumental in 2022 and beyond as we execute on helping patients fight cancer,” said Executive Chairman, Dr. Corey Goodman.

About Dr. Itziar Canamasas

Dr. Itziar Canamasas currently serves as the Head of Oncology Europe, Middle East, and Africa at Bayer AG. During her 20-plus years at Bayer, Dr. Canamasas has held various oncology leadership positions with expertise focused on global commercialization, strategic life-cycle development, and corporate strategy, including roles as VP of Global Marketing Oncology and Managing Director of Bayer Limited. Dr. Canamasas is also the Organizational Development Director for the Ambassador Program at the Healthcare Businesswomen’s Association.

“I am excited to join the Board at this pivotal junction in ALX Oncology’s growth trajectory. I look forward to working closely with the management team and fellow Board members to execute on advancing evorpacept to reach its full potential as a therapy for patients with hematological and solid tumors,” said Dr. Canamasas.

Dr. Canamasas holds an M.S. in Biology with distinction from the Universitat de Barcelona and a Ph.D. in Cancer Genetics from the University of Mainz.

About ALX Oncology

ALX Oncology is a publicly-traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with several leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team